A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure

High-risk myelodysplastic syndrome/acute myeloid leukemia patients have a very poor survival after azacitidine failure. Guadecitabine (SGI-110) is a novel subcutaneous hypomethylating agent which results in extended decitabine exposure. This multicenter phase II study evaluated the efficacy and safe...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Haematologica
Main Authors: Sébert, Marie, Renneville, Aline, Bally, Cécile, Peterlin, Pierre, Beyne-Rauzy, Odile, Legros, Laurence, Gourin, Marie-Pierre, Sanhes, Laurence, Wattel, Eric, Gyan, Emmanuel, Park, Sophie, Stamatoullas, Aspasia, Banos, Anne, Laribi, Kamel, Jueliger, Simone, Bevan, Luke, Chermat, Fatiha, Sapena, Rosa, Nibourel, Olivier, Chaffaut, Cendrine, Chevret, Sylvie, Preudhomme, Claude, Adès, Lionel, Fenaux, Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6669173/
https://ncbi.nlm.nih.gov/pubmed/30733271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2018.207118
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados